Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

References

• Dempke WCM, Fenchel K, Uciechowski P, Dale SP. Second- and third-generation drugs for immuno-oncology treatment-The more the better? Eur J Cancer. 2017;74:55–14. doi:10.1016/j.ejca.2017.01.001.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017;17(2):175–186. doi:10.1080/14737140.2017.1270208.
   PubMed Web of Science ®Google Scholar
• Richman LP, Vonderheide RH. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol Res. 2014;2(1):19–26. doi:10.1158/2326-6066.CIR-13-0152.
   PubMed Web of Science ®Google Scholar
• Todryk SM, Tutt AL, Green MH, Smallwood JA, Halanek N, Dalgleish AG, Glennie MJ. CD40 ligation for immunotherapy of solid tumours. J Immunol Methods. 2001;248(1–2):139–147. doi:10.1016/S0022-1759(00)00349-5.
   PubMed Web of Science ®Google Scholar
• Van Mierlo GJ, den Boer AT, Medema JP, Van der Voort EI, Fransen MF, Offringa R, Melief CJM, Toes REM. CD40 stimulation leads to effective therapy of CD40- tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A. 2002;99(8):5561–5566. doi:10.1073/pnas.082107699.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19(5):1035–1043. doi:10.1158/1078-0432.CCR-12-2064.
   PubMed Web of Science ®Google Scholar
• Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Totterman TH, Mangsbo SM. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res. 2014;2(1):80–90. doi:10.1158/2326-6066.CIR-13-0067.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH. The immune revolution: a case for priming, not checkpoint. Cancer Cell. 2018;33(4):563–569. doi:10.1016/j.ccell.2018.03.008.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612–1616. doi:10.1126/science.1198443.
   PubMed Web of Science ®Google Scholar
• Van Kooten C, Banchereau J. CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol. 1996;61:1–77.
   PubMed Web of Science ®Google Scholar
• Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA. 1995;92(10):4342–4346. doi:10.1073/pnas.92.10.4342.
   PubMed Web of Science ®Google Scholar
• Omari KM, Dorovini-Zis K. CD40 expressed by human brain endothelial cells regulates CD4+ T cell adhesion to endothelium. J Neuroimmunol. 2003;134(1–2):166–178. doi:10.1016/S0165-5728(02)00423-X.
   PubMed Web of Science ®Google Scholar
• Urban D, Thanabalasingam U, Stibenz D, Kaufmann J, Meyborg H, Fleck E, Gräfe M, Stawowy P. CD40/CD40L interaction induces E-selectin dependent leukocyte adhesion to human endothelial cells and inhibits endothelial cell migration. Biochem Biophys Res Commun. 2011;404(1):448–452. doi:10.1016/j.bbrc.2010.11.142.
   PubMed Web of Science ®Google Scholar
• Phipps RP. CD40: lord of the endothelial cell. Blood. 2008;112(9):3531–3532. doi:10.1182/blood-2008-08-175034.
   PubMed Web of Science ®Google Scholar
• Melter M, Reinders ME, Sho M, Pal S, Geehan C, Denton MD, Mukhopadhyay D, Briscoe DM. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood. 2000;96(12):3801–3808. doi:10.1182/blood.V96.12.3801.
   PubMed Web of Science ®Google Scholar
• Chiodoni C, Iezzi M, Guiducci C, Sangaletti S, Alessandrini I, Ratti C, Tiboni F, Musiani P, Granger DN, Colombo MP, et al. Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med. 2006;203(11):2441–2450. doi:10.1084/jem.20060844.
   PubMed Web of Science ®Google Scholar
• Flaxenburg JA, Melter M, Lapchak PH, Briscoe DM, Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol. 2004;172(12):7503–7509. doi:10.4049/jimmunol.172.12.7503.
   PubMed Web of Science ®Google Scholar
• Flati V, Pastore LI, Griffioen AW, Satijn S, Toniato E, D’Alimonte I, Laglia E, Marchetti P, Gulino A, Martinotti S, et al. Endothelial cell anergy is mediated by bFGF through the sustained activation of p38-MAPK and NF-kappaB inhibition. Int J Immunopathol Pharmacol. 2006;19(4):761–773. doi:10.1177/039463200601900406.
   PubMed Web of Science ®Google Scholar
• Dirkx AE, Oude Egbrink MG, Castermans K, Van der Schaft DW, Thijssen VL, Dings RP. Anti-angiogenesis Therapy Can Overcome Endothelial Cell Anergy and Promote Leukocyte-endothelium Interactions and Infiltration in Tumors. FASEB J. 2006;20:621–630.
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Damen CA, Mayo KH, Barendsz-Janson AF, Martinotti S, Blijham GH. Angiogenesis inhibitors overcome tumor induced endothelial cell anergy. Int J Cancer. 1999;80(2):315–319. doi:10.1002/(SICI)1097-0215(19990118)80:2<315::AID-IJC23>3.0.CO;2-L.
   PubMed Web of Science ®Google Scholar
• Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, Kreuger J, Dimberg A. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappaB-induced endothelial activation. Faseb J. 2015;29(1):227–238. doi:10.1096/fsb2.v29.1.
   PubMed Web of Science ®Google Scholar
• van Hooren L, Georganaki M, Huang H, Mangsbo SM, Dimberg A. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. Oncotarget. 2016;7(31):50277–50289. doi:10.18632/oncotarget.v7i31.
   PubMed Web of Science ®Google Scholar
• Lanitis E, Dangaj D, Irving M, Coukos G. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann Oncol. 2017;28:xii18–xii32. doi:10.1093/annonc/mdx238.
   PubMed Web of Science ®Google Scholar
• Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol. 2015;33:55–63. doi:10.1016/j.coi.2015.01.011.
   PubMed Web of Science ®Google Scholar
• Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607–615. doi:10.1038/nm.3541.
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 2016;37(3):193–207. doi:10.1016/j.it.2016.01.002.
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61–73. doi:10.1016/j.immuni.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Herve C, Gutierrez-Roelens I, Marbaix E, Sempoux C, et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res. 2015;3(2):161–172. doi:10.1158/2326-6066.CIR-14-0137.
   PubMed Web of Science ®Google Scholar
• Dai X, Zhu BT. Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: implications for its biological functions. J Histochem Cytochem. 2010;58(1):17–28. doi:10.1369/jhc.2009.953604.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi:10.1016/j.cels.2015.12.004.
   PubMed Web of Science ®Google Scholar
• Budhwani M, Mazzieri R, Dolcetti R. Plasticity of Type I interferon-mediated responses in cancer therapy: from anti-tumor immunity to resistance. Front Oncol. 2018;8:322. doi:10.3389/fonc.2018.00322.
   PubMed Web of Science ®Google Scholar
• Heiman M, Kulicke R, Fenster RJ, Greengard P, Heintz N. Cell type-specific mRNA purification by translating ribosome affinity purification (TRAP). Nat Protoc. 2014;9(6):1282–1291. doi:10.1038/nprot.2014.085.
   PubMed Web of Science ®Google Scholar
• Xue ZT, Sjogren HO, Salford LG, Widegren B. An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-gamma: potential therapeutic use in autoimmune diseases. Mol Immunol. 2012;51(2):101–111. doi:10.1016/j.molimm.2012.01.006.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210(7):1389–1402. doi:10.1084/jem.20130066.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok J. Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner. Cell Rep. 2015;13(2):412–424. doi:10.1016/j.celrep.2015.08.077.
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116. doi:10.1126/scitranslmed.3006504.
   PubMed Web of Science ®Google Scholar
• Guillonneau C, Hill M, Hubert FX, Chiffoleau E, Herve C, Li XL, Heslan M, Usal C, Tesson L, Ménoret S, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest. 2007;117(4):1096–1106. doi:10.1172/JCI28801.
   PubMed Web of Science ®Google Scholar
• Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim Y-S, Brechbiel MW, Gulley JL, et al. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget. 2016;7(25):37762–37772. doi:10.18632/oncotarget.v7i25.
   PubMedGoogle Scholar
• Moon YW, Hajjar J, Hwu P, Naing A. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer. 2015;3:51. doi:10.1186/s40425-015-0094-9.
   PubMed Web of Science ®Google Scholar
• Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115(17):3520–3530. doi:10.1182/blood-2009-09-246124.
   PubMed Web of Science ®Google Scholar
• Mullard A. IDO takes a blow. Nat Rev Drug Discov. 2018;17:307.
   Web of Science ®Google Scholar
• Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood. 2009;113(24):6102–6111. doi:10.1182/blood-2008-12-195354.
   PubMed Web of Science ®Google Scholar
• Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Giles FJ, Wainwright DA. Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy. Clin Cancer Res. 2015;21(24):5427–5433. doi:10.1158/1078-0432.CCR-15-0420.
   PubMed Web of Science ®Google Scholar
• Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest. 2010;120(11):3953–3968. doi:10.1172/JCI43490.
   PubMed Web of Science ®Google Scholar
• Georganaki M, van Hooren L, Dimberg A. Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer. Front Immunol. 2018;9:3081. doi:10.3389/fimmu.2018.03081.
   PubMed Web of Science ®Google Scholar
• Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412–416. doi:10.1038/nature11538.
   PubMed Web of Science ®Google Scholar
• Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den Boorn-konijnenberg D, Hömig-Hölzel C, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature. 2014;507(7490):109–113. doi:10.1038/nature13111.
   PubMed Web of Science ®Google Scholar
• Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36. doi:10.1186/gb-2013-14-4-r36.
   PubMed Web of Science ®Google Scholar
• Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005;21(16):3448–3449. doi:10.1093/bioinformatics/bti551.
   PubMed Web of Science ®Google Scholar
• Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5(11):e13984. doi:10.1371/journal.pone.0013984.
   PubMed Web of Science ®Google Scholar
• Baroukh C, Jenkins SL, Dannenfelser R, Ma’ayan A. Genes2WordCloud: a quick way to identify biological themes from gene lists and free text. Source Code Biol Med. 2011;6:15. doi:10.1186/1751-0473-6-15.
   PubMedGoogle Scholar
• Arvaniti E, Claassen M. Sensitive detection of rare disease-associated cell subsets via representation learning. Nat Commun. 2017;8:14825. doi:10.1038/ncomms14825.
   PubMed Web of Science ®Google Scholar